Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
- 4 November 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 387 (10016), 349-356
- https://doi.org/10.1016/s0140-6736(15)00515-2
Abstract
No abstract availableFunding Information
- Regado Biosciences
This publication has 27 references indexed in Scilit:
- Impact of Bleeding on Mortality After Percutaneous Coronary InterventionКАРДИОЛОГИЯ УЗБЕКИСТАНА, 2011
- A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trialAmerican Heart Journal, 2011
- First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary InterventionCirculation, 2010
- Aptamers as therapeuticsNature Reviews Drug Discovery, 2010
- Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery DiseaseCirculation, 2008
- A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitorJournal of Thrombosis and Haemostasis, 2008
- Factor IXa Inhibitors as Novel AnticoagulantsArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory goutArthritis & Rheumatism, 2007
- First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer TechnologyCirculation, 2006
- Transmission of a procoagulant signal from tissue factor-bearing cells to plateletsBlood Coagulation & Fibrinolysis, 1996